Collagenase Injection for Contracture Management
Part of paid clinical trials in Houston, Texas.
- Sponsor
- The University of Texas Health Science Center, Houston
- Study ID
- NCT07693556
- Phase
- EARLY_PHASE1
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Contracture
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Active XIAFLEX Collagenase injection — BIOLOGICALCollagenase is an enzyme that breaks down collagen, which is a key component of connective tissue, such as fascia. XIAFLEX is an FDA-Approved collagenase for treatment of Dupuytren's contracture with a palpable cord in the fingers, and Peyronie's disease in the penile tissue. In this research project, we plan to use collagenase to treat contracture in patients with neurological impairments, such as stroke, brain injury, and spinal cord injury. FDA guidelines will be followed for dosing and patient selection to minimize or reduce the risks.
Study Details
The overall goal is to investigate the effectiveness of a novel intervention - Collagenase injection, for contracture management in patients with neurological impairments, such as stroke, brain injury, and spinal cord injury.
Key Dates
- First listed
- Jul 9, 2026
- Start date
- Sep 1, 2026
- Status verified
- Jul 2026
- Primary completion
- May 31, 2031
- Completion
- Sep 30, 2031
Study Design
- Enrollment
- 15 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Active XIAFLEX Collagenase injection
Primary Outcome Measure
Change in spasticity as assessed by the Modified Ashworth Scale (MAS) [ Time Frame: Baseline before the intervention, follow up visits at 2 days (24 to 72 hours), 2 weeks, 1 month and 3 months post-injections ]
Central Contacts
- Sheng Li, MD, PhD(713) 797-7125
- Shengai Li, MS713-797-7561
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| The University of Texas Health Science Center at Houston | Houston | Texas | 77030 | - |
Find similar trials in Houston, TX
Related Studies
- Repurposing 5-Azacytidine for the Treatment of Muscle Contractures in Children With Cerebral PalsyPHASE1 · Enrolling By Invitation · Shirley Ryan AbilityLab · San Diego, California